Pneumococcal disease is an important cause of avoidable morbidity and mortality. In Britain the estimated annual incidences of pneumococcal pneumonia, bacteraemia and meningitis are 100/10, 7/10 and 0.5/10 respectively. 2 Population aging, and the growing problem of antibiotic resistant pneumococci make these problems of increasing public health importance. The current 23-valent pneumococcal va...

BACKGROUND Pneumococcal conjugate vaccines (PCV) reduce nasopharyngeal carriage of vaccine type (VT) pneumococci, an important driver of vaccine programs' overall benefits. The dosing schedule that best reduces carriage is unclear. METHODS We performed a systematic review of English language publications from 1994 to 2010 (supplemented post hoc with studies from 2011) reporting PCV effects on...

On February 20, 2013, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.) for children aged 6-18 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants who have not previou...

In Portugal, pneumococcal conjugate vaccines have been administered to children outside of the national immunization plan since 2001. We determined the serotype and antimicrobial susceptibility of 1265 isolates responsible for adult invasive pneumococcal infections (IPD) between 2009 and 2011 and compared the results with previously published data from 1999 to 2008. Serotypes 3 (12.6%), 7F (10....

Invasive diseases caused by Streptococcus pneumoniae (pneumococcus) are a major public health issue in Europe as well as worldwide. Severe diseases caused by pneumococci are pneumonia, meningitis and febrile bacteraemia; otitis media is a more common, but less serious manifestation of pneumococcal infection. Pneumococcus can affect all age groups but the bigger burden of disease is among childr...

OBJECTIVE To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine. DESIGN Economic evaluation using a cohort model from the perspective of healthcare providers. SETTING England. PARTICIPANTS People aged 2 years and older at increased risk of invasive pneumococcal disease due...

Introduction. Streptococcus pneumoniae is an important pathogen with high morbidity and mortality rates. The aim of this study was to evaluate the distribution of common serotypes and antimicrobial susceptibility of S. pneumoniae in Korea. Methods. A total of 378 pneumococcal isolates were collected from 2008 through 2014. We analyzed the serotype and antimicrobial susceptibility for both invas...

Pneumococcal pneumonia and invasive pneumococcal disease (IPD) remain a considerable cause of morbidity and mortality, with recent data showing a continued unacceptably high social and economic burden. Streptococcus pneumoniae can be isolated from 5-10% of healthy adults and 20-40% of healthy children1. Infection can result in a variety of clinical syndromes with meningitis, pneumonia, and seps...

A heptavalent pneumococcal conjugate vaccine (PCV-7) protects children against invasive pneumococcal disease. The aim of this study was to evaluate immunoglobulin subclass and serotype-specific pneumococcal antibody responses to vaccination in children with a history of recurrent or severe bacterial infections. Pneumococcal IgG, IgG1, IgG2 titres were assayed by ELISA, and nine serotype concent...